YTS 102
Alternative Names: GPC3 CXCRx STAR-T; GPC3-CAR-T cells; YT-GPC3; YTS102Latest Information Update: 28 Sep 2024
At a glance
- Originator China Immunotech
- Class Antineoplastics; CAR-T cell therapies; Gene therapies; Immunotherapies
- Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity No
Highest Development Phases
- No development reported Liver cancer
Most Recent Events
- 28 Sep 2024 No recent reports of development identified for preclinical development in Liver-cancer in China (IV, Infusion)
- 14 Feb 2022 China Immunotech suspends a planned phase I trial for Liver cancer (Second-line therapy or greater) in China, prior to enrollment initiation, as the company adjust the plan(IV) (NCT04506983)
- 10 Aug 2020 Preclinical trials in Liver cancer in China (IV)